Storia in 6 fonti

AstraZeneca: Gescheiterter Herzmedikamenten-Test belastet

Fast 26 Milliarden Euro Börsenwert gehen verloren, nachdem ein Test ergeben hat, dass ein neues Herzmedikament praktisch wirkungslos ist. Doch trotz des Rückschlags bleibt Astra-Zeneca auf starkem Wachstumskurs.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

faz.netStai leggendo1 g fa

AstraZeneca: Gescheiterter Herzmedikamenten-Test belastet

originale

Timeline cronologica

giovedì 9 luglio 2026·cnbc.com
AstraZeneca stock dives 9% after heart drug trial misses target
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
giovedì 9 luglio 2026·endpoints.news
AstraZeneca sinks on unexpected heart drug trial failure
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.

AstraZeneca: Gescheiterter Herzmedikamenten-Test belastet

Confronto fonti

AstraZeneca: Gescheiterter Herzmedikamenten-Test belastet

Timeline cronologica

AstraZeneca stock dives 9% after heart drug trial misses target

AstraZeneca sinks on unexpected heart drug trial failure

AstraZeneca sees stock market value slump by more than £20bn after drug setback

AstraZeneca stock dives 9% after heart drug trial misses target

AstraZeneca crolla in borsa a Londra dopo il flop del farmaco Wainua: il titolo perde fino al 9% |…

A Londra scivolone di Astrazeneca dopo fallimento trial Wainua per malattia cardiaca

AstraZeneca sinks on unexpected heart drug trial failure

AstraZeneca crolla in borsa a Londra dopo il flop del farmaco Wainua: il titolo perde fino al 9% | MilanoFinanza News

AstraZeneca sees stock market value slump by more than £20bn after drug setback

A Londra scivolone di Astrazeneca dopo fallimento trial Wainua per malattia cardiaca

AstraZeneca: Gescheiterter Herzmedikamenten-Test belastet